DRUGS MADE IN AMERICA ACQUIS
DMAANASDAQπ #3391 by market capUS Equity
$10.89β² $0.02 (+0.14%)
Market closed Β· at closeTrack DMAA
Get earnings, price moves & breaking news on Telegram
24hβ² 0.1%
7dβ² 0.1%
14dβ² 0.3%
30dβ² 0.6%
ytdβ² 5.6%
1yβ² 5.6%
π¦Market Cap
$264M
Small Cap
πRevenue Growth (YoY)
0.0%
Slowing
πGross Margin
0.0%
Thin
π΅FCF Margin
0.0%
Thin
βοΈP/S Ratio
0.0x
Cheap
Otter Score
β
Insufficient data
Trading Snapshot
- Day Range
- $10.88 β $10.88
- 52-Week Range
- $10.30 β $10.89
- Volume (shares)
- 11,253
- Avg Volume (shares)
- β
- Shares Outstanding
- 24.3M
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- 55.5
- P/S Ratio
- 0.0x
- EPS (TTM)
- $0.30
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +145.1%
DRUGS MADE IN AMERICA ACQUIS
DMAAFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$3Mβ² +587794.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$539Kβ² +182675.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
21.0Mβ² +145.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$6Kβ² +$7K YoY
About DRUGS MADE IN AMERICA ACQUIS
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
πQualityβ
β
β
β
β
πGrowthβ
β
β
β
β
βοΈValuationβ
β
β
β
β
π§Dilutionβ
β
β
β
β
Overall Score
Insufficient data
β/100
Analyst data unavailable.
Latest News & Updates
News unavailable.